North America Hormone Replacement Therapy Market

North America Hormone Replacement Therapy Market Analysis

The North America Hormone Replacement Therapy Market size is estimated at USD 5 billion in 2025, and is expected to reach USD 6.88 billion by 2030, at a CAGR of 6.60% during the forecast period (2025-2030).

Factors such as increasing awareness of post-menopausal issues among women, a rise in drug development with novel delivery systems, and hormonal imbalance disorders with a rising geriatric population are expected to drive the market. For instance, according to the May 2022 update by the National Institute of Aging, more than 1 million women in the United States experience menopause each year. Hence, a high prevalence of women undergoing menopause is likely to utilize hormone replacement therapy, thereby driving the market growth over the forecast period.

Furthermore, according to the Menopause Foundation of Canada Landmark Report published in October 2022, more than 95% of women experience symptoms related to menopause, such as hot flashes, cognitive changes, sexual dysfunction, sleep disturbances, and mood swings. Menopausal hormone therapy (MHT) is mostly helpful in alleviating the symptoms of menopause. MHT may also have cardiovascular benefits if taken early. Because the interaction between MHT and CVD is influenced by MHT preparation and the underlying cardiac risk. Recommendations for MHT use vary for women with CVD risk factors or those at high risk of CVD. Hence, with such benefits offered by hormone replacement therapy, the studied market is likely to drive market growth over the forecast period.

Moreover, an increase in research studies demonstrating the utilization and benefits of hormone replacement therapy for menopause is also likely to drive the market growth over the forecast period. For instance, according to the article published by the United States researchers in May 2023 in the International Journal of Women's Health, MHT showed significant effectiveness for the treatment of vasomotor symptoms (VMS) of menopause, and benefits may reduce risks of coronary heart disease (CHD), stroke, and venous thromboembolism (VTE), especially among women who are less than 10 years since menopause, less than 60 years old, and without significant cardiometabolic comorbidities or contraindications to MHT.

Thus, owing to the increase in the adoption of hormone replacement therapy during menopause and the extended benefits offered by hormone replacement therapy, the studied market is expected to witness significant growth over the forecast period. However, the high cost of hormone replacement therapy and the substantial risk of cancer associated with hormone replacement therapy are likely to hinder the market growth over the forecast period.

North America Hormone Replacement Therapy Market Trends

Menopause Segment is Expected to Witness Positive Growth Over the Forecast Period

Menopause is the time that marks the end of a woman's menstrual cycle, and it is diagnosed after a woman has gone 12 months without a menstrual period. Menopause is divided into three basic stages such as perimenopause, menopause, and post-menopause. Menopause can happen at an age ranging between 40 to 50 years. Hormone replacement therapy improves the quality of life and prolongs life for many elderly women, whether it is initiated at menopause or much later. The therapy helps elderly women maintain their estrogen levels. Factors such as an increase in the utilization of hormone replacement therapy during menopause and the high population of women undergoing menopause are expected to fuel the market growth over the forecast period. For instance, according to the data revealed during the North American Menopause Society (NAMS) 2022, 85% of perimenopausal and menopausal women experience a wide range of symptoms that clinically impact their quality of life. Hence, to reduce the complications related to menopause, HRT is widely used, which is likely to drive the segment growth over the forecast period.

Furthermore, a rise in the number of middle-aged women who undergo menopause is also likely to fuel market growth over the forecast period. For instance, according to the July 2024 update by Statistics Canada, approximately 1.2 million female population aged 50 to 54 years was present in Canada in 2023. Hence, a high population of middle-aged women is likely to undergo menopause and thereby expected to utilize the HRT, leading to segment growth over the forecast period. Furthermore, research studies depicting the importance of HRT during menopause are also expected to favor the segment growth over the forecast period. For instance,

Thus, owing to the high population of middle-aged women and menopause cases, the studied segment is expected to witness significant growth over the forecast period.

United States is Expected to Witness a Significant Growth Over the Forecast Period

United States (US) is expected to witness significant market growth owing to the rising geriatric female population, robust healthcare infrastructure, and the increase in hormonal imbalance diseases. For instance, according to the November 2022 update by Cuyuna Regional Medical Center, 64 million US women are 50 and older. Also, 1.1 billion women are expected to be menopausal due to women living longer by 2025. Hence, the high female population, which is middle-aged, is expected to drive the market growth in the US.

Furthermore, the increase in hormonal imbalance diseases is also likely to favor the market growth over the forecast period. For instance, according to the American Cancer Society 2024 update, 44,020 new cases of thyroid cancer (12,500 in men and 31,520 in women) cases are likely to be diagnosed in the US in 2024. Healthcare practitioners often prescribe thyroid hormone therapy to prevent cancer cells from further spreading. Hence, the high prevalence of thyroid diseases is expected to drive the market growth over the forecast period.

Furthermore, the presence of key players and the increase in product launches and regulatory approvals for hormone replacement therapy in the region is expected to bolster the market growth over the forecast period. For instance, in June 2023, Pfizer Inc, and OPKO Health Inc. received the U.S. Food and Drug Administration approval for NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for the treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.

Thus, due to the increase in female population and strategic activities by the key players, the United States is expected to witness significant growth over the forecast period.

North America Hormone Replacement Therapy Industry Overview

The North America hormone replacement therapy market is semi consolidated in nature due to the presence of several companies operating globally as well as regionally. A few of the major companies in the market are Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche, Novartis AG, and Novo Nordisk AS.

North America Hormone Replacement Therapy Market Leaders

North America Hormone Replacement Therapy Market News

• February 2024: Knight Therapeutics Inc., a specialty pharmaceutical company operating across the Pan-American region (excluding the USA), launched BIJUVA(estradiol and progesterone) capsules in Canada. BIJUVA is designed to treat moderate to severe vasomotor symptoms (VMS) linked to menopause in women who have an intact uterus.
• June 2023: Pfizer Inc. restocked the DUAVEE (conjugated estrogens/bazedoxifene), an estrogen-based menopause hormone therapy in the United States, with improved packaging following a voluntary recall. The recall was due to an issue associated with the packaging, which was rectified in the new launch.